Matthew Sorrentino to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Matthew Sorrentino has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
0.385
-
Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo. J Am Heart Assoc. 2026 02 03; 15(3):e46943.
Score: 0.176
-
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial. Lancet Neurol. 2025 Apr; 24(4):295-304.
Score: 0.166
-
The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol. 2005 Oct 10; 104(3):264-8.
Score: 0.043